Case Study on Dronabinol Delta-9 THC in Autism | cannabisMD

Case Study on Dronabinol (Delta-9-THC) in Autism

Dronabinol THC

Autism is a developmental disability; with symptoms usually becoming apparent during the early years of a persons life. It can severely affect ones capability to interact with others. Autism can be determined by certain behaviors and can affect each individual in a different manner depending on what spectrum the person may be categorized into. The single cause of autism is unknown, however, with an early diagnosis, better understanding and attainable support all results in improved outcomes.

The behaviors that would be displayed with someone with autism may include intense interests; late learning of language, trouble with making eye contact or managing a conversation, obsessive interests, low motor skills, sensitivity with the senses and lack of interest with peer relationships. However, since autism is a spectrum condition, the symptoms may vary depending on where the individual may be assorted.

There are treatments for autism, however, you cannot simply outgrow it. Autism is a lifelong diagnosis and with 1 in 59 Americans being on the spectrum, it is crucial to understand and accommodate for.

There are well known alterations of neurotransmitters in autistic people especially in the cerebral cannabinoid receptor system. It was therefore asked whether dronabinol could safely be used in autism and what outcomes could be achieved within an observation period of six months. Dronabinol, is derived from the cannabis plant and is usually used for cancer patients to treat towards nausea and vomiting.

Here is the full scientific article if you wish to download it.

During the six months follow-up, the subject received only dronabinol therapy. The maximum tolerated dose effect was reached at 2-1-3, total daily dose of 3,62 mg dronabinol. The ABC subscales significantly changed.

Hyperactivity decreased by 27 points, lethargy was reduced by 25 points and irritability by 12 points.

Stereotypic behaviour deCannabinoids November 21, 2010 decreased by 7 points and inappropriate speech improved by 6 points.

Jonathan Neilly
Jonathan Neilly
Jonathan Neilly is registered with the British Psychological Society, breaking the taboo on mental health issues is one of the driving forces in his life. His background in biomedicine gives him additional understanding of the factors that work together to influence the human condition.

Leave a Reply

Your email address will not be published. Required fields are marked *